Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Entera Bio Ltd.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-4.2% vs price
Base Case (Median)
46.5% vs price
Bull Case (75th pct.)
97.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| PE Comparable | $7.73 | 147.7% | Medium (25%) |
| Graham Number | $1.41 | -54.8% | Medium (40%) |
Based on 2 out of 7 methods, ENTX appears fairly valued at the current price of $3.12. The base case fair value of $4.57 implies 46.5% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.